Matches in SemOpenAlex for { <https://semopenalex.org/work/W390230693> ?p ?o ?g. }
- W390230693 endingPage "7" @default.
- W390230693 startingPage "460" @default.
- W390230693 abstract "Currently, there are several oxaliplatin combination regimens for first-line therapy of metastatic colorectal cancer (mCRC). In this study, we compared the survival outcomes of mCRC patients treated with bevacizumab in combination with either modified 5-FU/FA/oxaliplatin (mFOL- FOX6) or capecitabine/oxaliplatin (XELOX).We designed a two-arm retrospective study of mCRC patients with adenocarcinoma of the colon or rectum who were treated with bevacizumab and either mFOLFOX6 or XELOX and who had complete clinical and treatment data. We analysed their therapeutic responses, adverse events, progression-free survival (PFS), and overall survival (OS), and then determined whether there were any statistically significant differences.A total of 131 patients (85 male; 65% and 46 female; 35%) were evaluated. Fifty-seven patients (43.5%) were treated with bevacizumab and mFOLFOX6 and 74 (56.5%) with bevacizumab and XELOX. The median PFS was 9.1 months (95% CI, 4.9-13.1) and 10 months (95% CI, 4.2-15.9) in the mFOLFOX6 and XELOX arms, respectively (p=0.610). The median OS was 29 months (95% CI, 21.6- 34.3) and 27.5 months (95% CI 20-38) in the mFOLFOX6 and XELOX arms (p=0.812), respectively. The most common reason for treatment withdrawal was disease progression (102 patients; 91%) and the most common grade 3-4 toxicity was neuropathy (≤14%).Our results show that XELOX is a safe and effective alternative to mFOLFOX6 when combined with bevacizumab as first-line treatment for mCRC patients." @default.
- W390230693 created "2016-06-24" @default.
- W390230693 creator A5001194399 @default.
- W390230693 creator A5002010642 @default.
- W390230693 creator A5005907986 @default.
- W390230693 creator A5030027735 @default.
- W390230693 creator A5035194428 @default.
- W390230693 creator A5049099575 @default.
- W390230693 creator A5049354495 @default.
- W390230693 creator A5052985063 @default.
- W390230693 creator A5055562586 @default.
- W390230693 creator A5063673875 @default.
- W390230693 creator A5066618509 @default.
- W390230693 date "2015-05-27" @default.
- W390230693 modified "2023-10-14" @default.
- W390230693 title "Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer." @default.
- W390230693 cites W130193562 @default.
- W390230693 cites W152750528 @default.
- W390230693 cites W1968626722 @default.
- W390230693 cites W201798340 @default.
- W390230693 cites W2019607817 @default.
- W390230693 cites W2022594244 @default.
- W390230693 cites W2054062957 @default.
- W390230693 cites W2068725792 @default.
- W390230693 cites W2076668534 @default.
- W390230693 cites W2085705101 @default.
- W390230693 cites W2091321692 @default.
- W390230693 cites W2093252674 @default.
- W390230693 cites W2094634425 @default.
- W390230693 cites W2096651590 @default.
- W390230693 cites W2105427184 @default.
- W390230693 cites W2106787323 @default.
- W390230693 cites W2108923852 @default.
- W390230693 cites W2114780052 @default.
- W390230693 cites W2125447919 @default.
- W390230693 cites W2125468170 @default.
- W390230693 cites W2133671458 @default.
- W390230693 cites W2143743735 @default.
- W390230693 cites W2154662994 @default.
- W390230693 cites W2156726799 @default.
- W390230693 cites W2162158906 @default.
- W390230693 cites W2165388519 @default.
- W390230693 cites W2170332580 @default.
- W390230693 cites W2427263370 @default.
- W390230693 cites W2044928573 @default.
- W390230693 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26011336" @default.
- W390230693 hasPublicationYear "2015" @default.
- W390230693 type Work @default.
- W390230693 sameAs 390230693 @default.
- W390230693 citedByCount "1" @default.
- W390230693 countsByYear W3902306932023 @default.
- W390230693 crossrefType "journal-article" @default.
- W390230693 hasAuthorship W390230693A5001194399 @default.
- W390230693 hasAuthorship W390230693A5002010642 @default.
- W390230693 hasAuthorship W390230693A5005907986 @default.
- W390230693 hasAuthorship W390230693A5030027735 @default.
- W390230693 hasAuthorship W390230693A5035194428 @default.
- W390230693 hasAuthorship W390230693A5049099575 @default.
- W390230693 hasAuthorship W390230693A5049354495 @default.
- W390230693 hasAuthorship W390230693A5052985063 @default.
- W390230693 hasAuthorship W390230693A5055562586 @default.
- W390230693 hasAuthorship W390230693A5063673875 @default.
- W390230693 hasAuthorship W390230693A5066618509 @default.
- W390230693 hasConcept C121608353 @default.
- W390230693 hasConcept C126322002 @default.
- W390230693 hasConcept C143998085 @default.
- W390230693 hasConcept C197934379 @default.
- W390230693 hasConcept C2776694085 @default.
- W390230693 hasConcept C2776999253 @default.
- W390230693 hasConcept C2777802072 @default.
- W390230693 hasConcept C2777909004 @default.
- W390230693 hasConcept C2780456651 @default.
- W390230693 hasConcept C2780962732 @default.
- W390230693 hasConcept C526805850 @default.
- W390230693 hasConcept C71924100 @default.
- W390230693 hasConcept C90924648 @default.
- W390230693 hasConceptScore W390230693C121608353 @default.
- W390230693 hasConceptScore W390230693C126322002 @default.
- W390230693 hasConceptScore W390230693C143998085 @default.
- W390230693 hasConceptScore W390230693C197934379 @default.
- W390230693 hasConceptScore W390230693C2776694085 @default.
- W390230693 hasConceptScore W390230693C2776999253 @default.
- W390230693 hasConceptScore W390230693C2777802072 @default.
- W390230693 hasConceptScore W390230693C2777909004 @default.
- W390230693 hasConceptScore W390230693C2780456651 @default.
- W390230693 hasConceptScore W390230693C2780962732 @default.
- W390230693 hasConceptScore W390230693C526805850 @default.
- W390230693 hasConceptScore W390230693C71924100 @default.
- W390230693 hasConceptScore W390230693C90924648 @default.
- W390230693 hasIssue "2" @default.
- W390230693 hasLocation W3902306931 @default.
- W390230693 hasOpenAccess W390230693 @default.
- W390230693 hasPrimaryLocation W3902306931 @default.
- W390230693 hasRelatedWork W1953161284 @default.
- W390230693 hasRelatedWork W2020685114 @default.
- W390230693 hasRelatedWork W2075077394 @default.
- W390230693 hasRelatedWork W2098707609 @default.
- W390230693 hasRelatedWork W2127640925 @default.